Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,600

Employees17,600

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,600

Employees17,600

GILD Key Statistics

Market cap

131.81B

Market cap131.81B

Price-Earnings ratio

22.54

Price-Earnings ratio22.54

Dividend yield

2.89%

Dividend yield2.89%

Average volume

9.21M

Average volume9.21M

High today

$106.92

High today$106.92

Low today

$104.46

Low today$104.46

Open price

$106.92

Open price$106.92

Volume

6.05M

Volume6.05M

52 Week high

$119.96

52 Week high$119.96

52 Week low

$66.01

52 Week low$66.01

GILD News

Simply Wall St 14h

Gilead Sciences (NasdaqGS:GILD) Partners With Kymera In US$750 Million Cancer Treatment Deal

recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue degrader program targeting CDK2, enhancing its oncology pipeline. A...

Analyst ratings

60%

of 30 ratings

Buy

60%

Hold

40%

Sell

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.